Skip header and navigation

Refine By

106729 records – page 1 of 10673.

1,005 delayed days: a study of adult psychiatric discharge.

https://arctichealth.org/en/permalink/ahliterature244608
Source
Hosp Community Psychiatry. 1981 Apr;32(4):266-8
Publication Type
Article
Date
Apr-1981
Author
P A Barrette
Source
Hosp Community Psychiatry. 1981 Apr;32(4):266-8
Date
Apr-1981
Language
English
Publication Type
Article
Keywords
Adult
Canada
Hospitals, Community
Hospitals, Psychiatric - organization & administration
Humans
Length of Stay
Patient Acceptance of Health Care
Patient Discharge
Abstract
Delay in discharge of psychiatric patients frequently is attributed to the lack of available community resources, or to the unwillingness of the patient or his family to accept discharge or transfer to another facility. The role of the psychiatric system itself rarely is mentioned as a factor. A study of 138 psychiatric patients in a Canadian community hospital in 1978 showed that 35 per cent were judged to be delayed in their discharge. By far the greatest source of delay was the administration of the various psychiatric services within the system. Delayed patients were found to be statistically similar to nondelayed patients, except for the delayed patients tendency to be poorer and to be overrepresented on two of the six wards studied. The cost implications of the delays in discharge are discussed, as are suggestions for solving the problems within the administrative framework.
PubMed ID
7227988 View in PubMed
Less detail

The 1 alpha-hydroxylase locus is not linked to calcium stone formation or calciuric phenotypes in French-Canadian families.

https://arctichealth.org/en/permalink/ahliterature206213
Source
J Am Soc Nephrol. 1998 Mar;9(3):425-32
Publication Type
Article
Date
Mar-1998
Author
P. Scott
D. Ouimet
Y. Proulx
M L Trouvé
G. Guay
B. Gagnon
L. Valiquette
A. Bonnardeaux
Author Affiliation
Service de Néphrologie, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.
Source
J Am Soc Nephrol. 1998 Mar;9(3):425-32
Date
Mar-1998
Language
English
Publication Type
Article
Keywords
25-Hydroxyvitamin D3 1-alpha-Hydroxylase - genetics - metabolism
Adult
Calcium - urine
Canada
European Continental Ancestry Group - genetics
Family Health
Female
France - ethnology
Genetic Linkage
Genetic Markers - genetics
Humans
Kidney Calculi - enzymology - genetics
Male
Middle Aged
Nuclear Family
Pedigree
Phenotype
Vitamin D - blood
Abstract
Calcium urolithiasis is often associated with increased intestinal absorption and urine excretion of calcium, and has been suggested to result from increased vitamin D production. The role of the enzyme 1 alpha-hydroxylase, the rate-limiting step in active vitamin D production, was evaluated in 36 families, including 28 sibships with at least a pair of affected sibs, using qualitative and quantitative trait linkage analyses. Sibs with a verified calcium urolithiasis passage (n = 117) had higher 24-h calciuria (P = 0.03), oxaluria (P = 0.02), fasting and postcalcium loading urine calcium/creatinine (Ca/cr) ratios (P = 0.008 and P = 0.002, respectively), and serum 1,25(OH)2 vitamin D levels (P = 0.02) compared with nonstone-forming sibs (n = 120). Markers from a 9-centiMorgan interval encompassing the VDD1 locus on chromosome 12q13-14 (putative 1 alpha-hydroxylase) were analyzed in 28 sibships (146 sib pairs) of single and recurrent stone formers and in 14 sibships (65 sib pairs) with recurrent-only (> or = 3 episodes) stone-forming sibs. Two-point and multipoint analyses did not reveal excess in alleles shared among affected sibs at the VDD1 locus. Linkage of stone formation to the VDD1 locus could be excluded, respectively, with a lambda d of 2.0 (single and recurrent stone formers) and 3.25 (recurrent stone formers). Quantitative trait analyses revealed no evidence for linkage to 24-h calciuria and oxaluria, serum 1,25(OH)2 vitamin D levels, and Ca/cr ratios. This study shows absence of linkage of the putative 1 alpha-hydroxylase locus to calcium stone formation or to quantitative traits associated with idiopathic hypercalciuria. In addition, there is coaggregation of calciuric and oxaluric phenotypes with stone formation.
PubMed ID
9513904 View in PubMed
Less detail

The -1C to T polymorphism in the annexin A5 gene is not associated with the risk of acute myocardial infarction or sudden cardiac death in middle-aged Finnish males.

https://arctichealth.org/en/permalink/ahliterature53135
Source
Scand J Clin Lab Invest. 2005;65(2):133-40
Publication Type
Article
Date
2005
Author
K S Kaikkonen
S. Kakko
M L Kortelainen
J M Tapanainen
M J Savolainen
Y. Antero Kesäniemi
H V Huikuri
E R Savolainen
Author Affiliation
Division of Cardiology, Department of Internal Medicine, University of Oulu, Finland.
Source
Scand J Clin Lab Invest. 2005;65(2):133-40
Date
2005
Language
English
Publication Type
Article
Keywords
5' Untranslated Regions - genetics
Adult
Aged
Annexin A5 - genetics
Death, Sudden, Cardiac - epidemiology - etiology
Finland - epidemiology
Genetic markers
Genetic Predisposition to Disease
Genetic Screening
Humans
Male
Middle Aged
Myocardial Infarction - epidemiology - genetics
Polymorphism, Genetic
Research Support, Non-U.S. Gov't
Risk factors
Abstract
OBJECTIVE: A common polymorphism (-1C to T) in the translation initiation sequence of annexin A5 (ANV) gene has recently been associated with a decreased risk of acute myocardial infarction (AMI). The aim of the present study was to analyze the association between the ANV genepolymorphism and the risk of AMI and ischemic sudden cardiac death (SCD) in middle-aged Finnish males. MATERIAL AND METHODS: A case-control study involving three distinct groups of subjects was carried out: (1) victims of SCD (n=98), (2) survivors of AMI (n=212), and (3) randomly selected control subjects without any history of coronary heart disease (n=243). The ANV polymorphism was genotyped in each study group. RESULTS: Among the control group of healthy Finnish males the prevalence rates of the CC, CT, and TT genotypes were 83.1%, 15.2%, and 1.6%, respectively. Among the survivors of AMI, the prevalence rates of CC, CT, and TT were 79.7%, 20.3%, and 0%, respectively, and among the victims of SCD 83.7%, 16.3%, and 0%, respectively. No significant differences in the genotype or allele distributions were observed between the study groups. CONCLUSION: The -1C to T polymorphism in the ANV gene is not associated with the risk of AMI or SCD in middle-aged Finnish males.
PubMed ID
16025836 View in PubMed
Less detail

1H MRS studies in the Finnish boron neutron capture therapy project: detection of 10B-carrier, L-p-boronophenylalanine-fructose.

https://arctichealth.org/en/permalink/ahliterature172386
Source
Eur J Radiol. 2005 Nov;56(2):154-9
Publication Type
Article
Date
Nov-2005
Author
M. Timonen
L. Kankaanranta
N. Lundbom
J. Collan
A. Kangasmäki
M. Kortesniemi
A-M Häkkinen
A. Lönngren
S. Karjalainen
M. Rasilainen
J. Leinonen
T. Huitti
J. Jääskeläinen
M. Kouri
S. Savolainen
S. Heikkinen
Author Affiliation
Department of Physical Sciences, University of Helsinki, POB 64, FIN-00014, Helsinki, Finland.
Source
Eur J Radiol. 2005 Nov;56(2):154-9
Date
Nov-2005
Language
English
Publication Type
Article
Keywords
Adult
Aged
Boron - therapeutic use
Boron Compounds - analysis - blood
Boron Neutron Capture Therapy
Brain Neoplasms - pathology - radiotherapy
Carcinoma - pathology - radiotherapy
Female
Finland
Fructose - analogs & derivatives - analysis - blood
Glioblastoma - pathology - radiotherapy
Humans
Hydrogen
Isotopes - therapeutic use
Magnetic Resonance Spectroscopy - methods
Male
Neoplasm Recurrence, Local - pathology - radiotherapy
Paranasal Sinus Neoplasms - pathology - radiotherapy
Phantoms, Imaging
Plasma
Radiopharmaceuticals - therapeutic use
Abstract
This article summarizes the current status of 1H MRS in detecting and quantifying a boron neutron capture therapy (BNCT) boron carrier, L-p-boronophenylalanine-fructose (BPA-F) in vivo in the Finnish BNCT project. The applicability of 1H MRS to detect BPA-F is evaluated and discussed in a typical situation with a blood containing resection cavity within the gross tumour volume (GTV). 1H MRS is not an ideal method to study BPA concentration in GTV with blood in recent resection cavity. For an optimal identification of BPA signals in the in vivo 1H MR spectrum, both pre- and post-infusion 1H MRS should be performed. The post-infusion spectroscopy studies should be scheduled either prior to or, less optimally, immediately after the BNCT. The pre-BNCT MRS is necessary in order to utilise the MRS results in the actual dose planning.
PubMed ID
16233888 View in PubMed
Less detail

1H NMR studies on human plasma lipids from newborn infants, healthy adults, and adults with tumors.

https://arctichealth.org/en/permalink/ahliterature25704
Source
Magn Reson Med. 1989 Jan;9(1):35-8
Publication Type
Article
Date
Jan-1989
Author
S. Eskelinen
Y. Hiltunen
J. Jokisaari
S. Virtanen
K. Kiviniitty
Author Affiliation
Department of Biomedical Physics, University of Oulu, Finland.
Source
Magn Reson Med. 1989 Jan;9(1):35-8
Date
Jan-1989
Language
English
Publication Type
Article
Keywords
Adult
Female
Humans
Hydrogen
Infant, Newborn - blood
Lactates - blood
Lipoproteins - blood
Magnetic Resonance Spectroscopy - diagnostic use
Male
Methane - blood
Neoplasms - blood
Protons
Abstract
The 1H NMR spectra of the lipid region of human plasma from healthy adults, neonates, and patients with malignant and nonmalignant tumors have been recorded on a JNM-GX400 FT spectrometer operating at 399.6 MHz for protons. The chemical shifts of methylene and methyl groups of plasma lipids were measured with respect to the higher field component of the methyl proton resonance of the lactate molecule. The results show that there are changes in the chemical shifts of the methylene proton resonances among the plasma from healthy adults, adults with tumors, and neonates. The shifts observed in the case of cancer patients and neonates are in the direction opposite to the shift measured from the plasma of healthy adults. Thus, the observed changes cannot be explained by the activity in the cell proliferation of tissues which is high in the cases of both healthy neonates and patients with malignant tumors, but they most probably reflect the different lipoprotein compositions of neonates, healthy adults, and adults with tumors.
PubMed ID
2540395 View in PubMed
Less detail

The 1% of the population accountable for 63% of all violent crime convictions.

https://arctichealth.org/en/permalink/ahliterature259131
Source
Soc Psychiatry Psychiatr Epidemiol. 2014 Apr;49(4):559-71
Publication Type
Article
Date
Apr-2014
Author
Falk, O
Wallinius, M
Lundström, S
Frisell, T
Anckarsäter, H
Kerekes, N
Source
Soc Psychiatry Psychiatr Epidemiol. 2014 Apr;49(4):559-71
Date
Apr-2014
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aggression - psychology
Criminals - psychology - statistics & numerical data
Female
Humans
Male
Mental Disorders - epidemiology - psychology
Middle Aged
Registries
Risk factors
Substance-Related Disorders - epidemiology
Sweden
Violence - psychology - statistics & numerical data
Abstract
Population-based studies on violent crime and background factors may provide an understanding of the relationships between susceptibility factors and crime. We aimed to determine the distribution of violent crime convictions in the Swedish population 1973-2004 and to identify criminal, academic, parental, and psychiatric risk factors for persistence in violent crime.
The nationwide multi-generation register was used with many other linked nationwide registers to select participants. All individuals born in 1958-1980 (2,393,765 individuals) were included. Persistent violent offenders (those with a lifetime history of three or more violent crime convictions) were compared with individuals having one or two such convictions, and to matched non-offenders. Independent variables were gender, age of first conviction for a violent crime, nonviolent crime convictions, and diagnoses for major mental disorders, personality disorders, and substance use disorders.
A total of 93,642 individuals (3.9%) had at least one violent conviction. The distribution of convictions was highly skewed; 24,342 persistent violent offenders (1.0% of the total population) accounted for 63.2% of all convictions. Persistence in violence was associated with male sex (OR 2.5), personality disorder (OR 2.3), violent crime conviction before age 19 (OR 2.0), drug-related offenses (OR 1.9), nonviolent criminality (OR 1.9), substance use disorder (OR 1.9), and major mental disorder (OR 1.3).
The majority of violent crimes are perpetrated by a small number of persistent violent offenders, typically males, characterized by early onset of violent criminality, substance abuse, personality disorders, and nonviolent criminality.
Notes
Cites: JAMA Psychiatry. 2013 May;70(5):465-7123467760
Cites: Behav Genet. 2012 Jan;42(1):3-1821761238
Cites: Arch Gen Psychiatry. 2000 Oct;57(10):979-8611015816
Cites: Dev Psychopathol. 2001 Spring;13(2):355-7511393651
Cites: J Consult Clin Psychol. 1989 Dec;57(6):710-82600241
Cites: Arch Gen Psychiatry. 1992 Jun;49(6):476-831599373
Cites: Lancet. 1997 May 24;349(9064):1498-5049167458
Cites: Am J Psychiatry. 1997 Jun;154(6):840-59167513
Cites: Psychol Bull. 1998 Mar;123(2):123-429522681
Cites: Arch Gen Psychiatry. 1998 May;55(5):393-4019596041
Cites: Psychiatry Clin Neurosci. 2005 Feb;59(1):25-915679536
Cites: Sex Abuse. 2005 Jul;17(3):269-9216121839
Cites: Eur J Public Health. 2006 Jun;16(3):260-6616446293
Cites: Am J Psychiatry. 2006 Aug;163(8):1397-40316877653
Cites: Am J Epidemiol. 2006 Dec 15;164(12):1199-20817032695
Cites: Soc Psychiatry Psychiatr Epidemiol. 2007 Jun;42(6):477-8417450452
Cites: J Clin Psychiatry. 2008 Jan;69(1):12-2218312033
Cites: J Abnorm Psychol. 2008 May;117(2):396-40518489215
Cites: Int J Law Psychiatry. 2008 Aug-Sep;31(4):374-8318678408
Cites: BMC Psychiatry. 2008;8:9219032787
Cites: J Clin Psychiatry. 2009 Mar;70(3):362-919284931
Cites: PLoS Med. 2009 Aug;6(8):e100012019668362
Cites: Nord J Psychiatry. 2009;63(4):292-30019229735
Cites: Schizophr Bull. 2010 Jul;36(4):702-1218990713
Cites: Arch Sex Behav. 2010 Oct;39(5):1161-919888644
Cites: Psychol Med. 2011 Jan;41(1):97-10520334717
Cites: Arch Gen Psychiatry. 2010 Dec;67(12):1325-621135334
Cites: Clin Psychol Rev. 2011 Jul;31(5):872-8221550331
Cites: PLoS One. 2011;6(10):e2576822022445
Cites: Arch Gen Psychiatry. 2000 May;57(5):494-50010807490
PubMed ID
24173408 View in PubMed
Less detail

A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.

https://arctichealth.org/en/permalink/ahliterature206818
Source
Chest. 1998 Jan;113(1):131-41
Publication Type
Article
Date
Jan-1998
Author
R. Grossman
J. Mukherjee
D. Vaughan
C. Eastwood
R. Cook
J. LaForge
N. Lampron
Author Affiliation
Department of Respiratory Medicine, Mount Sinai Hospital, Toronto, ON.
Source
Chest. 1998 Jan;113(1):131-41
Date
Jan-1998
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Anti-Infective Agents - adverse effects - economics - therapeutic use
Bronchitis - drug therapy - economics
Canada
Chronic Disease
Ciprofloxacin - adverse effects - economics - therapeutic use
Cost-Benefit Analysis
Female
Follow-Up Studies
Health Care Costs
Hospitalization - economics
Humans
Male
Middle Aged
Predictive value of tests
Quality-Adjusted Life Years
Recurrence
Treatment Outcome
Abstract
To evaluate the costs, consequences, effectiveness, and safety of ciprofloxacin vs standard antibiotic care in patients with an initial acute exacerbation of chronic bronchitis (AECB) as well as recurrent AECBs over a 1-year period.
Randomized, multicenter, parallel-group, open-label study.
Outpatient general practice.
A total of 240 patients, 18 years or older with chronic bronchitis, with a history of frequent exacerbations (three or more in the past year) presenting with a type 1 or 2 AECB (two or more of increased dyspnea, increased sputum volume, or sputum purulence).
The assessment included AECB symptoms, antibiotics prescribed, concomitant medications, adverse events, hospitalizations, emergency department visits, outpatient resources such as diagnostic tests, procedures, and patient and caregiver out-of-pocket expenses. Patients completed the Nottingham Health Profile, St. George's Respiratory Questionnaire, and the Health Utilities Index. The parameters were recorded with each AECB and at regular quarterly intervals for 1 year. These variables were compared between the ciprofloxacin-treated group and the usual-care-treated group.
Patients receiving ciprofloxacin experienced a median of two AECBs per patient compared to a median of three AECBs per patient receiving usual care. The mean annualized total number of AECB-symptom days was 42.9+/-2.8 in the ciprofloxacin arm compared to 45.6+/-3.0 days in the usual-care arm (p=0.50). The overall duration of the average AECB was 15.2+/-0.6 days for the ciprofloxacin arm compared to 16.3+/-0.6 days for the usual-care arm. Treatment with ciprofloxacin tended to accelerate the resolution of all AECBs compared to usual care (relative risk=1.20; 95% confidence interval [CI], 0.91 to 1.58; p=0.19). Treatment assignment did not affect the interexacerbation period but a history of severe bronchitis, prolonged chronic bronchitis, and an increased number of AECBs in the past year were associated with shorter exacerbations-free periods. There was a slight, but not statistically significant, improvement in all quality of life measures with ciprofloxacin over usual care. The only factors predictive of hospitalization were duration of chronic bronchitis (odds ratio=4.6; 95% CI, 1.6, 13.0) and severity of chronic bronchitis (odds ratio=4.3; 95% CI, 0.8, 24.6). The incremental cost difference of $578 Canadian in favor of usual care was not significant (95% CI, -$778, $1,932). The cost for the ciprofloxacin arm over the usual care arm was $18,588 Canadian per quality-adjusted life year gained. When the simple base case analysis was expanded to examine the effect of risk stratification, the presence of moderate or severe bronchitis and at least four AECBs in the previous year changed the economic and clinical analysis to one favorable to ciprofloxacin with the ciprofloxacin-treated group having a better clinical outcome at lower cost ("win-win" scenario).
Treatment with ciprofloxacin tended to accelerate the resolution of all AECBs compared to usual care; however, the difference was not statistically significant. Further, usual care was found to be more reflective of best available care rather than usual first-line agents such as amoxicillin, tetracycline, or trimethoprim-sulfamethoxazole as originally expected. Despite the similar antimicrobial activities and broad-spectrum coverage of both ciprofloxacin and usual care, the trends in clinical outcomes and all quality of life measurements favor ciprofloxacin. In patients suffering from an AECB with a history of moderate to severe chronic bronchitis and at least four AECBs in the previous year, ciprofloxacin treatment offered substantial clinical and economic benefits. In these patients, ciprofloxacin may be the preferred first antimicrobial choice.
PubMed ID
9440580 View in PubMed
Less detail

A 1-year comparison of turbuhaler vs pressurized metered-dose inhaler in asthmatic patients.

https://arctichealth.org/en/permalink/ahliterature11215
Source
Chest. 1996 Jul;110(1):53-7
Publication Type
Article
Date
Jul-1996
Author
R A Pauwels
F E Hargreave
P. Camus
M. Bukoski
E. Ståhl
Author Affiliation
Department of Respiratory Diseases, University Hospital, Ghent, Belgium.
Source
Chest. 1996 Jul;110(1):53-7
Date
Jul-1996
Language
English
Publication Type
Article
Keywords
Administration, Inhalation
Adrenergic beta-Agonists - administration & dosage
Adult
Asthma - drug therapy - physiopathology
Bronchodilator Agents - administration & dosage
Budesonide
Comparative Study
Female
Glucocorticoids - administration & dosage
Humans
Male
Nebulizers and Vaporizers
Peak Expiratory Flow Rate
Pregnenediones - administration & dosage
Research Support, Non-U.S. Gov't
Terbutaline - administration & dosage
Abstract
An open, randomized, parallel-group study was conducted to investigate whether asthmatic patients, considered adequately treated with a corticosteroid and/or short-acting beta 2-agonist via pressurized metered-dose inhaler (pMDI), could be transferred to a corresponding nominal dose of budesonide and/or terbutaline via Turbuhaler, an inspiratory flow-driven multidose dry powder inhaler (Astra Draco; Lund, Sweden), without a decrease in the effect of treatment. One thousand four patients (555 women; mean age, 44 years; mean peak expiratory flow [PEF], 102% predicted normal value) were randomized and treated with either pMDI (current therapy) or Turbuhaler for 52 weeks. The variables studied were asthma-related events, morning PEF, and inhaler-induced clinical symptoms. Asthma-related events were defined in two ways: (1) sum of health-care contacts plus doublings or additions of steroids, and (2) number of 2 consecutive days with PEF less than 80% of baseline. Baseline was obtained from a 2-week run-in period while receiving previous therapy. No statistically significant difference was found in asthma-related events according to definition 1. According to definition 2, there was a statistically significant difference between the groups in favor of Turbuhaler (p = 0.008). The mean number of events was 1.7 with Turbuhaler and 2.2 with pMDI. The mean number of weeks per patient with a PEF less than 90% of baseline was 4.5 with Turbuhaler compared with 6.0 with pMDI (p = 0.002). The sum of inhaler-induced symptoms after 1 year of use was statistically significantly lower with Turbuhaler (0.40) than with pMDI (0.75) (p = 0.0001). In conclusion, budesonide and terbutaline in Turbuhaler offered a superior alternative to corticosteroids and bronchodilators delivered by pMDIs in the maintenance treatment of asthma.
PubMed ID
8681664 View in PubMed
Less detail

A 1-year follow-up of prescribing patterns of analgesics in primary health care.

https://arctichealth.org/en/permalink/ahliterature224422
Source
J Clin Pharm Ther. 1992 Feb;17(1):43-7
Publication Type
Article
Date
Feb-1992
Author
R. Ahonen
H. Enlund
V. Pakarinen
S. Riihimäki
Author Affiliation
Department of Social Pharmacy, University of Kuopio, Finland.
Source
J Clin Pharm Ther. 1992 Feb;17(1):43-7
Date
Feb-1992
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Analgesics
Drug Prescriptions - statistics & numerical data
Female
Finland
Humans
Male
Middle Aged
Primary Health Care - trends
Abstract
The prescription of analgesics and anti-inflammatory drugs (analgesics) was studied using computerized patient records from a Finnish health centre with a population base of some 27,000 inhabitants. A random sample of every fifth patient visiting the health centre in 1986 was chosen. This study sample consisted of 4,577 patients with 17,021 physician contacts and altogether 14,035 prescriptions during the 1-year follow-up: of these analgesics comprised 14.8%. The proportion of the study population who received at least one analgesic prescription was 23 +/- 1.2% (95% CI). The use of physician contacts as a base revealed 10.7 +/- 0.5% (95% CI) of the contacts with an analgesic prescription. The exposure to analgesics among males increased with age from 17% for those aged 15-34 years to 34% for those aged 75 years or more. Among women, exposure to analgesics increased from 17% (15-34 years) to 41% (75 years or more). Most of patients who received analgesic prescriptions were incidental users (one or two analgesic prescriptions per year). Only 4% of women and 3% of men were categorized as heavy users of analgesics (seven or more analgesic prescriptions per year). The proportion of heavy users increased with age and was highest in the oldest age-group (75 years or more). In order to make informed policy judgements about drug use in society, we need routine sales statistics and patient-specific drug-use data such as those presented in this paper.
PubMed ID
1548311 View in PubMed
Less detail

106729 records – page 1 of 10673.